Blockchain-based startup EncrypGen will take advantage of Murrieta Genomics' sequencing lab and business services to market its Gene-Chain platform for data sharing.
As consumer genomics firms ramp up marketing for Alzheimer's risk tests, one support group says experts should help people understand the results and potential negative effects.
Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
The genetic testing community is having a tough time deciphering FDA's intentions based on its authorization of 23andMe’s PGx test and a recent safety alert.
Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.
The market authorization came with a number of caveats and special requirements that 23andMe must follow when selling its PGx tests to consumers.
The project is informing participants of familial hypercholesterolemia genetic test results, and hereditary breast and ovarian cancer, and Lynch syndrome results will follow.
ADx Healthcare is selling an APOE test on the Helix marketplace, while HealthLytix and Dash Genomics are marketing a polygenic hazard score for late-onset Alzheimer's.
23andMe is evaluating how third-party services are impacting customers' experiences and would like to see those services be more complementary to its own efforts.
Indian DTC genomics company Mapmygenome has enlisted Israel-based Digital DNAtix to move its interpretation and personalized medicine services to a blockchain.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.